{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:44Z","timestamp":1788174584731,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The combination of ibrutinib plus venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment leverages their complementary mechanisms of action. Studies investigating IV typically begin with a short initial course of ibrutinib, followed by venetoclax introduction for a limited duration, typically 12 months. The Swiss Group for Clinical Cancer Research (SAKK) 34\/17 study is a single-arm, multicenter, phase 2 trial evaluating the effectiveness of a modified IV schedule in patients with relapsed\/refractory (R\/R) CLL. No prior exposure to BTK or BCL2 inhibitors was allowed. The lead-in phase with ibrutinib was extended to 6 months to reduce the tumor burden and related tumor lysis syndrome (TLS) risk. Additionally, the treatment phase with IV is prolonged to a minimum of 24 months to enhance the undetectable minimal residual disease (uMRD; 10\u20134) rate. The primary end point was the rate of complete response or complete response with incomplete bone marrow recovery (CR\/CRi) with uMRD in both bone marrow (BM) and peripheral blood (PB). Secondary end points included assessing the proportion of patients transitioning to a low-risk category for TLS after receiving ibrutinib lead-in. Of the 30 enrolled patients with R\/R CLL, 40.0% achieved uMRD CR\/CRi by intention-to-treat analysis, and 53.3% showed uMRD in the BM and PB. After the lead-in period with ibrutinib, 57.1% of patients achieved a low risk of TLS. At cycle 31, the progression-free survival rate was 89.9%. These results contribute to the increasing body of evidence supporting the idea that a longer IV duration is beneficial for enhancing therapeutic effectiveness. This trial was registered at www.clinicaltrials.gov as #NCT03708003.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026879","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T12:08:16Z","timestamp":1740571696000},"page":"2587-2598","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: the SAKK 34\/17 trial"],"prefix":"10.1182","volume":"145","author":[{"given":"Adalgisa","family":"Condoluci","sequence":"first","affiliation":[{"name":"1Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"2Clinic of Hematology, Department of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-9807","authenticated-orcid":false,"given":"Ilaria","family":"Romano","sequence":"additional","affiliation":[{"name":"1Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"2Clinic of Hematology, Department of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dietrich","sequence":"additional","affiliation":[{"name":"3Swiss Group for Clinical Cancer Research Competence Center, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Pini","sequence":"additional","affiliation":[{"name":"1Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"St\u00fcssi","sequence":"additional","affiliation":[{"name":"2Clinic of Hematology, Department of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"},{"name":"4Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2993-8062","authenticated-orcid":false,"given":"Gisela","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"3Swiss Group for Clinical Cancer Research Competence Center, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Cantoni","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[{"name":"6Department of Oncology and Hematology, Kantonsspital Graub\u00fcnden, Chur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mey","sequence":"additional","affiliation":[{"name":"6Department of Oncology and Hematology, Kantonsspital Graub\u00fcnden, Chur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Widmer","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology and Hematology, University Hospital Z\u00fcrich, University of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology and Hematology, University Hospital Z\u00fcrich, University of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gregor","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Luzerner Kantonsspital, Luzern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Heim","sequence":"additional","affiliation":[{"name":"9Division of Hematology, University Hospital of Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-2988","authenticated-orcid":false,"given":"Martin","family":"Andres","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-6454","authenticated-orcid":false,"given":"Rudolf","family":"Benz","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Oncology, Spital Thurgau, Muensterlingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"1Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"2Clinic of Hematology, Department of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"},{"name":"4Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025052911213897900_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2025052911213897900_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2017.159","article-title":"BCL2 and miR-15\/16: from gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ"},{"issue":"10","key":"2025052911213897900_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"2025052911213897900_bib4","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2025052911213897900_bib5","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"34","key":"2025052911213897900_bib6","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025052911213897900_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"2025052911213897900_bib8","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-22-0504","article-title":"Effective tumor debulking with ibrutinib before initiation of venetoclax: results from the CAPTIVATE minimal residual disease and fixed-duration cohorts","volume":"28","author":"Barr","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"31","key":"2025052911213897900_bib9","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025052911213897900_bib10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2025052911213897900_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"},{"issue":"25","key":"2025052911213897900_bib12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025052911213897900_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cancergencyto.2009.08.021","article-title":"Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia","volume":"196","author":"Lu","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"2025052911213897900_bib14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1309\/AJCPOEFP3SLX6HXJ","article-title":"Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features","volume":"135","author":"Huh","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2025052911213897900_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2025052911213897900_bib16","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome [published correction appears in N Engl J Med. 2018;379(11):1094]","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025052911213897900_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood-2019-131732","article-title":"Combined ibrutinib and venetoclax in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) [abstract]","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2025052911213897900_bib18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2025052911213897900_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-136960","article-title":"Continued long term responses to ibrutinib + venetoclax treatment for relapsed\/refractory CLL in the Blood Cancer UK TAP Clarity trial [abstract]","volume":"136","author":"Hillmen","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2025052911213897900_bib20","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"22","key":"2025052911213897900_bib21","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025052911213897900_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025052911213897900_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.24.01192","article-title":"End point surrogacy in first-line chronic lymphocytic leukemia","volume":"43","author":"Simon","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025052911213897900_bib24","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2025052911213897900_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"31","key":"2025052911213897900_bib26","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025052911213897900_bib27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2025052911213897900_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.17718","article-title":"Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma","volume":"195","author":"Moia","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2025052911213897900_bib29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025052911213897900_bib30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41375-023-01901-4","article-title":"Venetoclax consolidation in high-risk CLL treated with ibrutinib for \u22651 year achieves a high rate of undetectable MRD","volume":"37","author":"Thompson","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"2025052911213897900_bib31","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"2025052911213897900_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/22\/2587\/2376606\/blood_bld-2024-026879-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/22\/2587\/2376606\/blood_bld-2024-026879-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:21:46Z","timestamp":1748517706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/22\/2587\/535762\/Ibrutinib-lead-in-followed-by-venetoclax-plus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":32,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,5,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026879","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,29]]},"published":{"date-parts":[[2025,5,29]]}}}